TEL:020-31701980      FAX:020-31701979     E-mail:sales@mx008.com
China Mingxuan
Service Hotline:020-3171980
搜索

News
MX trends
industry trends
fair information
 
Micro-channel
 
Information details You are here:Home >> News >> industry trends
 
Health insurance payment standard five big trend prediction, enterprise how to deal with?
 
Author:中国铭铉 企划部  Release Time:2017-4-26 10:49:01  Number Browse:399
 
Medical network on April 26 - in addition to change the way to charge payment reform, and promoting the medical service price reform, health care payment standard is key. In view of the standard are the standard of medical insurance fund pays medical insurance directory drugs, in the case of a basic universal health care, standards will directly affect the price and affect the drug works and life cycle. The author combed the people club department "medicare payment standard draft" (hereinafter referred to as the "draft") and the characteristics of paid around the standard solution, explore the future trend, enterprises deal with Suggestions. 
 
National & local policies 
 
People club department from February 2017 to joint health development planning commission on "paper" to solicit comments from various ministries and agencies, the paper put forward according to the drug in principle of generic standards, standards, according to the actual transaction price (including tender, retail stores, online pharmacies, large wholesale and secondary bargaining, etc.), the number of comprehensive consideration, at the same time explore similar drug prices compared to other regions, economic factors and drugs, payment standard adjustment once every two years, the standard after implementation detailed evaluation and analysis work, overall the spirit health charged fees. 
 
Has been introduced in the implementation of the payment standard and in a region and the latest solution features as follows: 
 
 
 
Trend prediction 
 
Comprehensive above countries paper and related documents and tender as a result, the author thinks that medicare pay standard will present the following trend: 
 
1. The state will guidance, concrete floor plan shall be formulated by the provinces. No. 2. The hair 13 legalise "secondary bargaining", and puts forward start led by food drug administration drugs ex-factory price to the traceability system, so the lowest price is only part of the health insurance payment standard threshold, varieties of the whole market all link price information will be the basis of standards, the provinces depending on the scope of medical insurance fund strength with reference to different price factors, wealthy provinces such as zhejiang will be relatively loose. 3. The treatment for relatively bullish, auxiliary and poor nutrition drug trends. The guide is not only consistent with national varieties of key monitoring policy, and fujian province as the reform pioneer for mining policy also embodies the spirit. 4. Domestic generics will meet market opportunities. Whether people club department is the common name of the journal paper rules and fujian scheme for expired drugs wouldn't have indicated that the dynamic. 5. With exclusive specifications deviate sword peak type to raise prices will no longer have the advantage. People club department "draft" similar medicines reference and plan of fujian province and the common name and on behalf of the product standards have shown that direction. 
 
Companies cope with advice 
 
According to the trend, the author suggested that companies focus on the following work: 
 
1. The whole link maintenance drug prices, system considering the price strategy; 2. To speed up the generics consistency evaluation work, first to become the first pay the price with the original drug varieties; 3. Speed up key large varieties of clinical path, the guidelines to be included in the work, improve the variety of clinical treatment of status; 4. Involvement in drug economics evidence-based research, multidimensional improve payment standard; 5. Acquisition, introduced varieties advantage field, become the new profit source. (the author is Shanghai pharmaceutical strategic development institute special researcher) 
 
Previous article:Exclusive data analysis to see green channel drugs listed speed quickly
Next article:Internal medicine electricity policy dividend not expected industry differentiation
 
Log in  Website Map All right reserved by China Mingxuan, Guangzhou ICP #16026227
    

粤公网安备 44011202000029号